Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Alcohols Stories

2013-12-05 08:29:22

SOCRATES compares ticagrelor versus aspirin for the prevention of major vascular events in patients with acute ischaemic stroke or transient ischaemic attack THEMIS compares ticagrelor versus placebo for the long-term prevention of major vascular events in patients with Type 2 diabetes at high cardiovascular risk MISSISSAUGA, ON, Dec. 5, 2013 /CNW/ - AstraZeneca has announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company's largest...

2013-12-05 04:21:04

FDA Reclassification of Hydrocodone to Schedule II Could Boost Sales. PALO ALTO, CA, Dec. 5, 2013 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that work on the name change to Praxsyn Corporation is nearing completion and that the Company expects to be able to file a request with FINRA early next week along with filing the necessary filings and disclosures with the SEC and the State of Illinois. Furthermore, the audit of Mesa Pharmacy, Inc.'s...

2013-12-03 16:25:16

LONDON, Dec. 3, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, has announced that the initial findings of its clinical trial with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health, supports Lightlake's intranasal delivery of naloxone as a promising innovative treatment for opioid overdose....

2013-12-03 08:33:07

STAMFORD, Conn., Dec. 3, 2013 /PRNewswire/ -- Purdue Pharma L.P. and Impax Laboratories, Inc. announced today that the companies have agreed to resolve the patent infringement lawsuits between them now pending in the United States District Court for the Southern District of New York concerning certain Purdue patents, including patents for abuse-deterrent technology, protecting OxyContin® (oxycodone HCl controlled-release) Tablets CII ("OxyContin"). According to the agreement, Purdue and...

2013-12-03 08:31:41

NORTHBROOK, Ill., Dec. 3, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and a five-year extension of market exclusivity if a product receiving such a designation is approved in the United States. These...

Oxycodone, Hydrocodone Drugs Of Choice For Opioid Abusers
2013-12-03 07:37:18

April Flowers for redOrbit.com - Your Universe Online In the past 15 years, prescription opioid abuse has reached epidemic levels. Researchers investigating why abusers favor one prescription medication over another have discovered that oxycodone and hydrocodone are the drugs of choice for 75 percent of opioid-dependent people. Oxycodone is the most popular drug over all, according to a study published in the journal PAIN, because of the high quality of the high for those who were after...

2013-12-02 16:21:09

DUBLIN, Ireland, December 2, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/k7xrmh/isobutanol_cas) has announced the addition of the "Isobutanol (CAS 78-83-1) Market Research Report 2012" [http://www.researchandmarkets.com/research/k7xrmh/isobutanol_cas ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Isobutanol (CAS 78-83-1) Market Research Report 2012 presents...

2013-12-02 16:20:53

DUBLIN, Ireland, December 2, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r38crn/natural_menthol) has announced the addition of the "Natural Menthol Crystals (CAS 2216-51-5) Market Research Report 2012" [http://www.researchandmarkets.com/research/r38crn/natural_menthol ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Menthol Crystal (CAS 2216-51-5) Market...

2013-12-02 08:30:12

Phase 3 to begin first quarter 2014; Fast track designation confirmed for NDA program RALEIGH, N.C., Dec. 2, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it engaged in a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development program for Clonidine Topical Gel that will allow the program to proceed to Phase 3 clinical studies in the first quarter of 2014. (Logo:...

2013-12-02 08:24:01

DUBLIN, December 2, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/v9nqqm/methanol_2013) has announced the addition of the "Methanol: 2013 World Market Outlook and Forecast up to 2017" [http://www.researchandmarkets.com/research/v9nqqm/methanol_2013 ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Methanol [http://www.researchandmarkets.com/research/v9nqqm/methanol_2013 ]: 2013 World...